show the actuarial OS and DFS, respectively, based on patient's score. As can been seen, patients with score 2 actually had superior OS and DFS in comparison to those with score 1, as did patients with score 4 in comparison to score 3. There was no significant difference in OS (P ¼ 0.07) or DFS (P ¼ 0.18) between patients with scores 1 and 4.
The (12;21)(p13;q22) translocation resulting in TEL/AML1 gene fusion is generally associated with a good prognosis and a high cellular sensitivity to L-asparaginase (L-Asp).
1,2 L-Asp hydrolyses asparagine and glutamine resulting into cellular depletion of these amino acids.
Krejci et al 3 studied changes in cell proliferation of t(12;21)-positive and t(12;21)-negative ALL cells after exposure to L-Asp. In correspondence with our data, 2 their data indicate that leukemic cells are able to upregulate asparagine synthetase (AS) gene expression upon nutrient stress induced by L-Asp. In addition, our work and Krejci's work show that AS was unexpectedly higher expressed in t(12;21)-positive ALL cells compared to t(12;21)-negative patients. These important findings contradict the general hypothesis that resistance to L-Asp is caused by an elevated basic cellular level of AS and/or by the selective ability of only resistant cells to rapidly induce the expression of the AS gene upon L-Asp exposure, 4 since t(12;21)-positive ALL cells are more sensitive to L-Asp compared to t(12;21)-negative ALL patients.
1,2 Besides induction of expression of AS, Krejci et al observed that L-Asp selectively prevents S-phase entry of a t(12;21)-positive cell line, but not a t(12;21)-negative cell line. Since AML1 is involved in the regulation of the G 1 to S cell cycle transition 5, 6 and TEL/AML1 converts AML1 from functioning as a transcriptional activator to a transcriptional repressor, 7 we investigated whether t(12;21)-positive patients already show this cell cycle arrest at initial diagnosis, independent from L-Asp treatment.
To this aim, the cell cycle of 75 t(12;21)-positive and 116 t(12;21)-negative ALL patients at initial diagnosis obtained from the DCOG was analysed by propidium-iodide staining of nuclei, as measured by flow cytometry (Figure 1 ). The percentage of cells in S phase is lower in t(12;21)-positive ALL (median: 6.8%) compared to t(12;21)-negative ALL (median: 8.5%; P ¼ 0.017). This finding might also contribute to our and Krejci's observations that AS expression is higher in t(12;21)-positive ALL compared to t(12;21)-negative ALL at diagnosis, as AS was described to be compensationally increased when cells could not proceed through the cell cycle. 8 Krejci et al showed that high AS expression is associated with a favorable outcome within t(12;21)-positive ALL. In our cohort of 41 t(12;21)-positive ALL, which is comparable to Krejci's cohort, however, we could not confirm this: high AS expression did not correlate with a higher disease-free survival (Figure 2a ) and AS expression did not differ between t(12;21)-positive ALL patients with and without subsequent relapse (Figure 2b) .
We hypothesize that t(12;21)-positive ALL cells already at diagnosis have impaired potential to proceed from G 1 into S phase due to the fact that TEL/AML1 represses the target (ie cell cycle-associated) genes of AML1. This matches perfectly with the higher AS expression in these cells at diagnosis compared to t(12;21)-negative ALL cells, since AS transcription is increased in cells that are hampered to proceed through the cell cycle. Nutrition stress caused by L-Asp even enhances this increase in AS expression. Probability of disease-free survival analysis (pDFS) in t(12;21)-positive ALL with high (n ¼ 21, 5-years pDFS 67722%) and low (n ¼ 20, 5-years pDFS 56721%) expression of AS. The median value (1.2) was used as a cutoff for the separation into high and low expression of AS (a). AS expression in t(12;21)-positive ALL patients at diagnosis with (n ¼ 10) subsequent relapse compared to t(12;21)-positive ALL patients in continuous complete remission (CCR) (n ¼ 31) (MWU: P40.05) (b). AS mRNA was determined by real-time quantitative PCR using the same conditions as described previously.
